28/09/2017
Nanobiotix shortlisted for People's Choice Award at IR Magazine Global Forum ! We count on your support !
Global Forum - People's Choice Voting Form Please click the link to complete this form.
Nanobiotix
Partager
Nanobiotix is a leading nanomedicine company that intends to revolutionize radiotherapy, making it m
NANOBIOTIX, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. NANOBIOTIX is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the effica
28/09/2017
Nanobiotix plans to conduct its 1st clinical trial in combination in the US: NBTXR3 w/ immune checkpoint inhibitors
Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer http://bit.ly/2kNcm0A
Nanobiotix Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting http://bit.ly/2ewpntq
Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe http://bit.ly/2cpgsHh
It's the homestretch for Nanobiotix to be the 2016! We still need your vote! http://bit.ly/1Teqt7T
Buzz of BIO Voting | 2016 BIO International Convention Vote for the Buzz of BIO! Vote for your favorite innovative biotech company in the Pipelines of Promise and Technologies of Tomorrow categories. One vote per person, per day will be strictly enforced. See contest rules. The companies with the most votes in each category will win one complimentary Co…
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category http://bit.ly/16K9Muj
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category | nanobiotix Paris, France, 7 November, 2013 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of
Retrouvez la Lettre aux actionnaires n°1 de Nanobiotix icihttp://www.nanobiotix.eu/wp-content/files_mf/1390403867Nanobiotix_newlsetter_1_novembre2013.pdf
Nanobiotix obtient un financement de 2,8 M€ de bpifrance
(ex OSEO) pour accélérer le développement de son produit
leader NBTXR3 dans une nouvelle indication http://bit.ly/1cRpweg
Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a... Through ETPN (European Technology Platform of Nanomedicine), Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine
26/06/2013
Nanobiotix: selection of NBTX-IV and collaboration with the for development http://bit.ly/19B2XuM
Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration... Characterization studies to be undertaken by the US National Cancer Institute’s Nanotechnology Characterization Laboratory Paris, France, 26 June, 2013 –
Vous voulez que votre école soit école la plus cotée à Paris ?
Cliquez ici pour réclamer votre Listage Commercial.
Cliquez ici pour réclamer votre Listage Commercial.
Emplacement
Type
Site Web
Adresse
60, Rue De Wattignies
Paris
75012